0001127602-19-021658.txt : 20190614 0001127602-19-021658.hdr.sgml : 20190614 20190614165121 ACCESSION NUMBER: 0001127602-19-021658 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190612 FILED AS OF DATE: 20190614 DATE AS OF CHANGE: 20190614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAKAMI HOOMAN CENTRAL INDEX KEY: 0001610035 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36820 FILM NUMBER: 19899481 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY STREET 2: MSLC300 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Medtronic plc CENTRAL INDEX KEY: 0001613103 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FISCAL YEAR END: 0426 BUSINESS ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 01135314381700 MAIL ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Ltd DATE OF NAME CHANGE: 20150112 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Holdings Ltd DATE OF NAME CHANGE: 20140711 FORMER COMPANY: FORMER CONFORMED NAME: Kalani I Ltd DATE OF NAME CHANGE: 20140709 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-06-12 0001613103 Medtronic plc MDT 0001610035 HAKAMI HOOMAN 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 1 EVP & Group President Diabetes Ordinary Shares 2019-06-12 4 M 0 31731 78.00 A 95337 D Ordinary Shares 2019-06-12 4 S 0 31731 97.49 D 63606 D Ordinary Shares 2019-06-12 4 S 0 20933 97.49 D 42673 D Stock Option (Right to Buy) 78.00 2019-06-12 4 M 0 31731 0 D 2016-08-03 2025-08-03 Ordinary Shares 31731 10578 D The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.22 to $97.96, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $97.95, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This balance increased by 959 shares due to exempt transactions such as dividend reinvestment and Employee Stock Purchase Plan. These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. /s/ Perry F. Sekus, attorney-in-fact 2019-06-14 EX-24 2 doc1.txt POWER OF ATTORNEY (PUBLIC): POA HAKAMI POWER OF ATTORNEY Know all by these presents, that the undersigned, director or officer, or both, of Medtronic plc, hereby constitutes and appoints each of Bradley E. Lerman, Martha Ha, Thomas L. Osteraas, Perry F. Sekus and Anne M. Ziebell signing singly, the undersigned?s true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 and any rule or regulation of the SEC; (2) execute for and on behalf of the undersigned, in the undersigned?s capacity as an officer and/or director of Medtronic plc (the ?Company?), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4, 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact?s discretion. The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact?s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned?s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5 with respect to the undersigned?s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney shall supersede any and all existing Powers of Attorney with respect to the subject matter hereof. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28 day of March, 2019. /s/ Hooman C. Hakami Hooman C. Hakami